Oxygenta Pharmaceutical net loss narrows 66% as revenue surges 144% in Q1FY27
Oxygenta Pharmaceutical Limited posted a Q1FY27 net loss of ₹2.10 crore, a 66% improvement from the previous year, fueled by a 144% revenue surge to ₹36.99 crore. Despite higher expenses and finance costs from ECLGS borrowings, the company narrowed its loss significantly. The Board also appointed PCR & Associates as Cost Auditors and reconstituted the POSH Committee.
*this image is generated using AI for illustrative purposes only.
Oxygenta Pharmaceutical Limited reported a significant improvement in its financial health for the first quarter of FY27, with net losses narrowing by 66% year-on-year to ₹2.10 crore. The Hyderabad-based pharmaceutical manufacturer achieved this turnaround primarily through a robust 144% surge in revenue from operations, which climbed to ₹36.99 crore from ₹15.13 crore in the corresponding period of the previous year. This top-line growth signals strengthening demand and operational scale, although the company continues to navigate margin pressures that have kept it in the red for the quarter.
The Board of Directors approved the unaudited financial results during a meeting held on July 27, 2026, at the company’s corporate office in Hyderabad. Statutory auditors A.M Reddy & D.R Reddy conducted the limited review in accordance with Standard on Review Engagements (SRE) 2410 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. In addition to approving the results, the Board appointed M/s. PCR & Associates as Cost Auditors for FY27, subject to shareholder ratification, and scheduled the Annual General Meeting for August 21, 2026.
Financial Performance Highlights
Total revenue for the quarter reached ₹37.02 crore, up from ₹15.30 crore in Q1FY26. However, total expenses also expanded significantly to ₹39.53 crore from ₹23.44 crore, reflecting higher production volumes and increased financing costs. Cost of materials consumed rose to ₹23.40 crore, while finance costs nearly quadrupled to ₹2.46 crore from ₹0.63 crore. This increase in interest burden is partly attributed to new borrowings under government support schemes, specifically ₹3.99 crore availed under the Emergency Credit Line Guarantee Scheme (ECLGS).
| Particulars | Q1FY27 (₹ Lakh) | Q1FY26 (₹ Lakh) | Change | Q4FY26 (₹ Lakh) |
|---|---|---|---|---|
| Revenue from Operations | 3,699.69 | 1,513.47 | +144% | 4,961.40 |
| Total Expenses | 3,952.75 | 2,343.99 | +69% | 5,106.67 |
| Loss Before Tax | (250.73) | (814.80) | -69% | (127.97) |
| Net Profit / (Loss) | (210.37) | (610.61) | -66% | (170.39) |
| Basic EPS (₹) | (0.57) | (1.65) | -65% | (0.45) |
Despite the revenue growth, the company recorded an operational loss before tax of ₹2.51 crore, compared to ₹8.15 crore in Q1FY26. A deferred tax credit of ₹0.40 crore helped reduce the final net loss. Earnings per share stood at a loss of ₹0.57, an improvement from the loss of ₹1.65 in the prior year period.
What the Numbers Show
The divergence between revenue growth and expense inflation highlights ongoing margin pressure. While revenue more than doubled year-on-year, total expenses grew by 69%, indicating that input costs and financing charges are absorbing much of the top-line gain. The sharp rise in finance costs suggests increased leverage, corroborated by the disclosure of ₹3.99 crore in ECLGS assistance. While this injection supports liquidity, it adds to the interest burden, potentially delaying the path to operational profitability. Additionally, the company disclosed gaps in identifying MSME creditors and has requested self-declarations from suppliers to improve compliance accuracy.
Corporate Governance Updates
Beyond financials, the Board reconstituted the POSH Committee effective July 27, 2026. Ms. Kurapati Divya serves as Presiding Officer, supported by internal members Ms. Kuchipudi Jyothi, Ms. B. Rajitha, Ms. S. Chandraleka, and Ms. Yempally Sindhu, along with external member Ms. D. Rajeswari. These appointments ensure compliance with workplace safety regulations as the company scales operations.
Historical Stock Returns for Oxygenta Pharmaceutical
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.45% | -2.21% | +0.27% | -19.38% | -53.03% | +121.62% |
How will the increased interest burden from ECLGS borrowings impact Oxygenta's timeline to achieve operational profitability?
What specific strategies is management implementing to address the widening gap between 144% revenue growth and only 69% expense control?
Will the appointment of PCR & Associates as Cost Auditors lead to stricter internal controls that might further compress short-term margins?
20
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
